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Abstract
In many organs, including the intestine and skin, cancers originate from cells of
the stem or progenitor compartment. Despite its nomenclature, the cellular origin
of hepatocellular carcinoma (HCC) remains elusive. In contrast to most organs,
the liver lacks a defined stem cell population for organ maintenance. Previous
studies suggest that both hepatocytes and facultative progenitor cells within the
biliary compartment are capable of generating HCC. As HCCs with a progenitor
signature carry a worse prognosis, understanding the origin of HCC is of clinical
relevance. Here, we used complementary fate-tracing approaches to label the
progenitor/biliary compartment and hepatocytes in murine hepatocarcinogenesis.
In genotoxic and genetic models, HCCs arose exclusively from hepatocytes
but never from the progenitor/biliary compartment. Cytokeratin 19-, A6- and α-
fetoprotein-positive cells within tumors were hepatocyte derived. In summary,
hepatocytes represent the cell of origin for HCC i...
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Hepatocellular carcinoma (HCC) is the third leading cause of cancer mortality world-wide. 
Despite its nomenclature, the cellular origin of HCC remains elusive with hepatocytes and 
progenitor cells representing sources for newly generated hepatocytes in chronic liver injury 
and subsequently developing HCC. Determining the cellular source for HCC has high 
relevance for primary and secondary prevention strategies, as HCCs with progenitor signature 
carry a worse prognosis. Here, we employed complementary cell fate tracing approaches to 
label progenitor cells and hepatocytes in murine hepatocarcinogenesis. Tumors arose from 
hepatocytes but not progenitor cells in genetic, genotoxic and dietary HCC models. Almost all 
A6-, AFP- and cytokeratin 19-positive cells within tumors but not in the surrounding liver 
were derived from hepatocytes. In summary, our findings suggest that hepatocytes are the 
main source for HCC in mice, and that progenitor signature does not reflect progenitor origin 
but rather de-differentiation of hepatocyte-derived tumor cells. 
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INTRODUCTION 
Hepatocellular carcinoma (HCC) is the third leading cause of cancer mortality world-wide 
with approximately 700,000 new cases diagnosed every year (1, 2). HCC typically develops 
in patients with chronic liver disease. Among these, viral hepatitis, non-alcoholic fatty liver 
disease and alcoholic liver disease are the leading causes for HCC (2). Chronic liver injury, 
triggering permanent hepatocellular damage, hepatocyte regeneration and inflammation, is 
thought to be the unifying principle that promotes carcinogenesis in these 
pathophysiologically distinct diseases. In the developing liver, bipotent hepatoblasts 
differentiate into hepatocytes and cholangiocytes and function as a main cellular source for 
both lineages (3). However, in the adult liver cell turnover is minimal, and bipotent 
progenitors are typically absent (3). As hepatocytes themselves are endowed with an almost 
infinite capacity to regenerate (4), regeneration following most types of injury or following 
partial hepatectomy is achieved from the hepatocyte pool without major contribution of 
progenitor cells (3, 5). However, when liver injury is chronic and when the ability of mature 
hepatocytes to proliferate is blocked, a reserve cell compartment – often termed oval cells or 
liver progenitor cells (LPC)  – expands in patients and in experimental injury models, and 
may contribute to the formation of hepatocytes (3, 4, 6-10). However, several recent fate 
tracing studies have challenged a major role for LPC in the formation of hepatocytes showing 
either no or only very little contribution to the hepatocyte pool (5, 11-15). On the other hand, 
the LPC/biliary compartment is capable to generate functional hepatocytes in zebrafish (16), 
indicating that the contribution of LPC may be model-, disease- or species-specific. 
Moreover, other studies support that hepatic stellate cells (HSCs) may function as multi-
potent progenitor cells that generate functional hepatocytes and cholangiocytes (17). Thus, 
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three different cellular sources, hepatocytes, LPC and HSCs, may in theory function as 
progenitor cells and cellular source for newly generated hepatocytes. 
Despite its nomenclature, the cellular origin of HCC remains elusive. Of note, the expansion 
of LPC has most consistently been noted after treatment with hepatic carcinogens (18, 19), 
which has led to the suggestion that HCC may be derived from LPC (18, 20, 21). Moreover, 
the expression of progenitor markers and accumulation of LPC is commonly observed in 
rodent models as well as in human HCC (22, 23). Therefore, the reemergence of LPC in the 
chronically injured liver may link regeneration to hepatocarcinogenesis. Moreover, as HCC 
with a progenitor signature is clinically more aggressive, it has been suggested that the 
progenitor origin of HCC determines tumor biology and negatively affects outcome (23). 
Importantly, both LPC and hepatocytes have the capacity to generate tumors in vivo when 
transduced with H-Ras and SV40LT (24). However, the relative contribution of these two cell 
types to cancer formation in the context of chronic hepatocellular injury in vivo remains 
unknown. The high degree of plasticity in the liver is further highlighted by recent studies 
showing that cholangiocarcinoma can not only be derived from cholangiocytes (25) but also 
from hepatocytes (26, 27). Based on these findings in cholangiocarcinoma, it is conceivable 
that there are also multiple cellular sources for HCC. Using complementary strategies to label 
LPC, hepatocytes and HSCs, we demonstrate that hepatocytes but neither LPC nor HSCs 
function as cellular source for HCC. Moreover, LPC found in HCC were derived from 




HCC does not originate from liver progenitor cells. 
To test the hypothesis that HCC is derived from the LPC compartment we used tamoxifen-
inducible osteopontin-(OPN)-iCreERT2 x ROSA26RYFP mice (OPN-Cre mice) to label 
progenitor and biliary cells. Tamoxifen injection in the post-natal period leads to 
recombination of the ROSA26RYFP locus and to permanent expression of yellow fluorescent 
protein (YFP) in OPN-expressing cells.  As reported elsewhere (12), upon tamoxifen 
injection, YFP expression is restricted to LPC and cholangiocytes and does not occur in 
hepatocytes, stellate, or Kupffer cells (Suppl.Fig.1). Using this system, between 69 and 82% 
of the progenitor and biliary compartment and their progeny were permanently tagged with 
YFP in this study (Fig.1C,H, Suppl.Fig.1A) and thus, development of YFP+-HCC would 
indicate a progenitor/biliary origin.  
First, HCCs were induced by chronic administration of diethylnitrosamine (DEN) resulting in 
HCC development in the setting of chronic injury, inflammation and fibrosis (28). Tamoxifen 
was injected at postpartum (pp) d21 (n=44) followed after a 4 week wash-out period by 
repeated DEN administration. At time of sacrifice, macroscopic tumors were observed in all 
livers (Fig.1A and Table 1), they were well delineated, and exhibited enlargement of the 
hepatocyte plates, high proliferative index, disruption of the reticulin network, absence of 
portal tracts and focal expression of α-fetoprotein (AFP) and OPN (Fig.1B-D). Altogether, 
250 tumors were histologically evaluated by an experimental pathologist (C.S.) and diagnosed 
as HCC. YFP immunostaining was performed to determine the cell source of HCC. In all of 
250 tumors, YFP expression was missing (Table 1) and only seen in CK-19+ and OPN+ bile 
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duct cells and ductular reaction (DR) that surrounds the tumors (Fig. 1C,D). In a second 
model, HCCs were induced by a single DEN injection to 15-day-old (d15) OPN-Cre mice. 
Tamoxifen was injected before (pp d9-10; n=16) or after (pp d21-22; n=25) DEN. The 
efficiency and specificity of the lineage tracing was equivalent (≈70%) and independent of the 
time of tamoxifen administration, and macroscopic tumors developed (Suppl.Fig.2A,B) in 50 
and 70% of the mice within 18 and 9 months, respectively (Table 1), consistent with the 
notion that tamoxifen treatment, in particular when given immediately before tumor 
induction, delays or inhibits tumor development (29). 240 tumors induced by this method 
were diagnosed as HCC. YFP expression was absent in all HCC (Table 1), while bile ducts 
and the DR found surrounding the tumors were YFP-positive (Suppl.Fig.2C,D). These 
findings were further confirmed in OPN-CreERT2 mice treated with the combination DEN 
and CCl4, which mimics hepatocarcinogenesis in the setting of liver fibrosis (30). In this 
model, HCCs also displayed typical features of HCC, including loss of collagen IV staining, 
high proliferation and expression of progenitor genes AFP, Prom1, and H19 (Fig.1F,I). 
Again, none of the tumors were labeled with YFP whereas bile duct in non-tumor liver were 
YFP-positive (Fig.1F-H, Table 1).  In a second model of LPC labeling, induced by the 
combination of tamoxifen-inducible K19-CreERT (31) and Cre reporter ZsGreen, none of the 
arising DEN+CCl4-induced HCCs was derived from K19-CreERT-labeled LPC (Suppl.Fig.3, 
Table 1). In summary, the absence of LPC-labeled tumors confirms that in multiple genotoxic 
DEN-induced hepatocarcinogenesis models and in different Cre-transgenic mice for LPC 
labeling, HCCs do not arise from progenitor or biliary cells. 
Genotoxic HCC originates from hepatocytes. 
As we found no evidence for the LPC compartment serving as the cellular source of HCC, we 
7 !
next investigated the alternative hypothesis that hepatocytes constitute the cellular source for 
HCC. To selectively label and trace hepatocytes during hepatocarcinogenesis, we employed 
an adeno-associated virus serotype 8, expressing Cre recombinase under the control of the 
hepatocyte-specific thyroxin-binding globulin promoter (AAV8-TBG-Cre) in combination 
with ROSA26loxP-mTom-stop-loxP–mGFP (mTom/mGFP) or ROSA26loxP-stop-loxP–ZsGreen1 (ZsGreen) 
Cre reporter mice. In ZsGreen Cre reporter mice, this approach labeled > 96% of hepatocytes, 
without labeling any other hepatic compartment including F4/80-positive Kupffer cells, the 
cytokeratin-positive biliary and LPC compartments, desmin-positive HSCs or endomucin-
positive endothelial cells, as determined by immunohistochemistry and confocal imaging 
(Suppl.Fig.4A,C-G). This analysis was further confirmed by qPCR of FACS-sorted cells that 
expressed the green fluorescent Cre reporter ZsGreen and showed at least the same level of 
Alb and Ttr expression as primary hepatocytes, but virtually no expression of cholangiocyte 
markers Krt7 and Krt19, HSC markers Des and Lrat, endothelial cell markers Pecam (CD31) 
and vWF, and macrophage markers Emr1 (F4/80) and Cd68 (Suppl.Fig.4B). Together, these 
data confirm efficient and highly specific labeling of hepatocytes by AAV8-TBG-Cre similar 
to previous studies (32, 33). Following AAV8-TBG-Cre infection at pp d12, we employed 
either single agent DEN (data not shown), or the combination of DEN+CCl4 to trigger 
hepatocarcinogenesis. These well-established protocols resulted in the development of well-
delinated tumors in 100% of mice (Fig.2A). Although the average hepatocyte labeling rate in 
the mTom-mGFP reporter mice was slightly below 96%, we observed an average rate of 
99.7% macroscopically and microscopically mGFP-positive tumors (n=10 mice, 185 out of 
186 tumors), i.e. hepatocyte-derived tumors, in DEN+CCl4-treated mice (Fig.2A-D, Table 2). 
Because hepatocyte labeling did not reach 100% and because we never observed any tumor 
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arising from the LPC compartment by our complementary LPC labeling approaches, we 
consider it most likely that the single GFP-negative tumor arose from unlabeled hepatocytes 
rather than from the LPC compartment. Although tumors were macroscopically entirely 
green, microscopic analysis revealed the presence of unrecombined non-hepatocyte-derived 
Tomato-positive cells that consisted predominantly of CD31-positive endothelial cells and 
F4/80-positive macrophages, confirming hepatocyte-specific labeling by our approach also 
within tumors (Suppl.Fig.5). Tumors were clearly defined as HCCs by pathological 
examination, loss of the normal hepatic reticulin and collagen IV staining pattern, increased 
expression of the proliferation marker Ki67, altered expression pattern of Gp73, loss of β-
catenin, upregulation of glutamine synthetase (Fig.2E). Histological analysis revealed a wide 
range of growth patterns including trabecular, steatotic, solid and cytoplasmatic inclusions 
(data not shown). Accordingly, tumors were diverse when analyzed by array comparative 
genomic hybridization (aCGH), demonstrating chromosomal aberrations in each investigated 
mouse, with a wide range of genomic alterations rather than a specific pattern (Fig.2F). Of 
note, comparison of genomic alteration in DEN+CCl4-induced HCC to a well-characterized 
set of human cryptogenic HCC (34) demonstrated gains and losses of loci in various 
chromosomal regions congruent with genomic alterations in human HCC (Fig.2G), further 
confirming the relevance of the herewith employed model.  Moreover, tumors expressed high 
levels of Gpc3, Golm1, mKi67, Tff3 and Tspan8 mRNA (Fig.2H). Importantly, every single 
DEN+CCl4-induced tumor that we examined contained at least one magnitude higher 
expression levels of progenitor markers Afp and H19, and almost all also contained much 
higher levels of Prom1 (Fig.2I). These data clearly exclude the possibility that hepatocyte 
origin in the DEN+CCl4 model is due to the lack of progenitor signature in these tumors. To 
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additionally address the possibility that LPC origin may only be revealed in models in which 
HCC arises in the setting of higher progenitor cell presence and turnover, we employed the 
combination of DEN with either CDE diet or DDC diet (11, 12). Although the labeling of 
hepatocytes was less efficient in these experiments than in the above DEN+CCl4 experiments, 
98.3% of DEN+CDE-induced tumors and 95.6% of DEN+DDC-induced tumors being 
macroscopically and microscopically GFP-positive (Suppl.Fig.6A-D). When only mice with 
at least 90% hepatocytes labeling were included in the analysis, 100% of tumors were GFP-
positive (data not shown), again suggesting that the few GFP-negative tumors in DEN+CDE 
and DEN+DDC experiments were a result of incomplete hepatocyte labeling rather than 
being LPC-derived.  Similar to the DEN+CCl4 model, DEN+CDE- and DEN+DDC-induced 
tumors showed high expression of HCC markers and progenitor markers (Suppl.Fig.6E-F, 
Table 2).  
 
HCC originates from hepatocytes in non-genotoxic HCC models 
To exclude that our observations on hepatocyte origin are specific to the employed models or 
caused by preferential metabolism of carcinogens in hepatocytes, we additionally tested 
cellular origin in DEN-free HCC models. For this purpose, we first investigated Mdr2ko mice 
which spontaneously develop inflammation, fibrosis and HCC, thus reproducing the sequence 
of events that lead to the majority of human HCCs (35). In the Mdr2ko model, AAV8-TBG-
Cre-mediated hepatocyte labeling via ZsGreen Cre reporter exceeded 96.8%, without labeling 
desmin-positive HSCs, F4/80-positive Kupffer cells, cytokeratin-positive cholangiocytes, or 
endomucin-positive endothelial cells (Suppl.Fig.7A). As this model not only lacks 
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confounding effects of hepatocellular DEN metabolism but also incorporates an abundance of 
LPC markers in the injured liver (Fig.3H), it provides an ideal setting to test in an unbiased 
manner from which cell population HCCs derive in the chronically injured, inflamed and 
fibrotic liver. All HCCs from Mdr2ko mice (n=7 mice, 20 out of 20 tumors) arose from 
AAV8-TBG-Cre labeled hepatocytes with macroscopic and microscopic ZsGreen tumor 
fluorescence (Fig.3A-D, Table 2) and co-localization of ZsGreen with HNF4α within tumors 
(Fig.3E). Tumors from Mdr2ko mice were typical HCCs with altered collagen IV expression, 
high expression of proliferation marker Ki-67, and upregulation of Golm1, mKi67, Tff3 and 
Tspn8 mRNA (Fig.3F-G), as determined by immunohistochemistry and qPCR. The few 
ZsGreen-negative cells within tumors were endomucin-positive endothelial cells, F4/80-
positive Kupffer cells (Suppl.Fig.7B). To further confirm these findings in another non-
genotoxic model, we determined whether hepatocyte-specific deletion of PTEN triggers 
HCC. PTEN is a tumor suppressor gene that shows reduced expression in about 50% of 
human HCC and inverse correlation with survival (36), and whose deletion by Albumin-Cre – 
which deletes in both the hepatocyte and LPC/biliary compartment (Suppl.Fig.8) -  triggers 
HCC development in mice (37). To provide evidence for hepatocytes as the cellular source of 
HCC in a genetic model, we either deleted PTEN specifically in hepatocytes via AAV8-TBG-
Cre or in the progenitor/biliary compartment via tamoxifen-inducible K19-Cre-ERT (31) 
AAV8-TBG-Cre-induced hepatocyte-specific deletion of PTEN resulted in the development 
of tumors with HCC features including increased glypican 3, Ki-67, keratin and pAkt 
expression (Suppl.Fig.9A-B, Table 2) and tumors were derived from hepatocytes as 
demonstrated by green fluorescence (Suppl.Fig.9C,D).  By contrast, K19-driven PTEN 
deletion resulted in an expansion of the cytokeratin-positive biliary compartment but never 
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led to HCC development (Suppl.Fig.9D-E). These data again demonstrate that the 
LPC/biliary compartment is not endowed with the capacity to form HCCs in mice. Finally, 
we also subjected OPN-Cre mice to chronic treatment with CDE-deficient diet as a 
complementary LPC labeling approach. This model was accompanied by a florid DR. HCCs 
were less common than in other models but were YFP-negative and hence not of LPC origin 
(Suppl.Fig.9G-H, Table 1). Together, these data provide multiple lines of evidence that 
hepatocytes and not LPC are also the cellular source of HCC in non-genotoxic tumor models.  
Hepatic stellate cells do not represent a cellular source for HCC. 
As HSCs have been show to act as an alternative source of LPC and hepatocytes (17), we 
wanted to determine whether HSC-derived LPC or hepatocytes may be the source for HCC. 
For this purpose, HSCs were labeled by Lrat-Cre in combination with ZsGreen or TdTomato 
mice, a system that efficiently and selectively tags HSCs in the liver (38). In line with our 
previous studies in multiple injury models (38), we did not detect a significant number of 
HSC-derived hepatocytes in mice that underwent injury-driven hepatocarcinogenesis induced 
by DEN+CCl4 (data not shown). Moreover, we did not find any tumors that were derived 
from Lrat-Cre-labeled cells (Fig.4A-C), with all fluorescent cells within tumors being desmin-
positive (Fig.4D) and HNF4α- and cytokeratin-negative (Suppl.Fig.10A). Similar 
observations were made in the Mdr2ko model, where no tumor cell was derived from Lrat-
Cre-labeled HSCs (Fig.4E,F,H, Suppl.Fig.10B). In both models, tumors revealed typical HCC 
characteristics such as altered collagen IV and Gp73 expression patterns and increased Ki-67 
staining (Fig.4C,G). While most tumors contained moderate numbers of Lrat-Cre-labeled 
cells, some tumors in both the DEN+CCl4 and Mdr2ko models displayed stronger 
accumulation of Lrat-Cre-labeled desmin-positive HSCs (Suppl.Fig.10C,D). However, even 
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in the few tumors that showed strong Cre reporter fluorescence, fluorescent cells co-localized 
with desmin without any overlap of Lrat-Cre-induced Cre reporter TdTomato with either 
HNF4α or cytokeratin (Suppl.Fig.10E,F). These findings are consistent with our data on the 
exclusive contribution of hepatocytes to HCC formation in the DEN+CCl4 and the Mdr2ko 
models, and further exclude that HSC-derived hepatocytes as cellular source of HCCs. 
Progenitor cells within HCCs originate from hepatocytes. 
Consistent with our data showing high mRNA expression of progenitor markers AFP, Prom1 
and H19 in tumors (Fig.1I, Fig.2I, Suppl.Fig.6F), we observed abundant A6- and AFP-
positive, and to a lesser extent cytokeratin 19 (K19)-positive cells within HCC nodules in all 
DEN-based models, (Fig.1C,G, Fig.5A-C,E,F,  Suppl.Fig.2C-D, Suppl.Fig. 11, 
Suppl.Fig.12A-B, Suppl.Fig.13A-B). Instead of interpreting these markers as a sign of 
progenitor, we investigated the alternative hypothesis that AFP-, A6- and cytokeratin 19-
positive cells within HCC may be hepatocyte-derived cells that underwent de-differentiation. 
Confocal microscopy demonstrated that in AAV8-TBG-Cre mice virtually all A6-positive 
cells within DEN+CCl4-, DEN+DDC- and DEN+CDE-induced tumors also co-expressed 
mGFP (Fig.5A, Suppl.Fig. 11, Suppl.Fig.12B, Suppl.Fig.13B), thus demonstrating their 
hepatocyte origin. These data were confirmed by AFP and K19 staining, which showed that 
AFP-positive cells (Fig.5C, Suppl.Fig.11, Suppl.Fig.12A, Suppl.13A) and K19-positive cells 
(Fig.5B, Suppl.Fig.11) within tumors were mGFP-positive and therefore hepatocyte-derived. 
In contrast, there were almost no A6-positive cells that co-expressed mGFP outside of the 
tumors (Fig.5A,D, Suppl.Fig.11, Suppl.Fig.12B, Suppl.Fig.13B). Moreover, only a low 
amount of K19-positive cells outside the tumor areas were mGFP-positive (Fig.5B,D). 
Similar findings were made in the Mdr2ko model, in which most K19-positive and A6-
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positive cells within tumors but not in the surrounding liver were hepatocyte derived 
(Suppl.Fig.14A-B). Consistent with these findings, we observed in OPN-Cre mice that A6-
positive cells within tumors were YFP-negative whereas the A6-positive ductular reaction 
surrounding tumors was YFP-positive (Fig.5E,H). K19 staining confirmed that YFP-positive 
cells outside the tumors expressed K19 while K19-positive cells within HCC were YFP-
negative (Fig.5F,H, Suppl.Fig.2C-D). AFP positive cells were only found within the tumors 
and were YFP negative (Fig. G). Together, these data suggest that A6-, K19 and AFP-positive 
cells within tumors are hepatocyte-derived, but that most A6- and K19-positive cells outside 
the tumors (AFP-positive cells were extremely rare outside tumors – Fig.5D) were derived 
from LPC/biliary compartment. 
DISCUSSION 
Despite its nomenclature, the cellular source of HCC remains elusive. Hepatocytes are not 
only the target of oncogenic hepatotrophic viruses and most hepatotoxins, but also have a 
stem-cell like capacity for nearly infinite regeneration (39), making them a primary candidate 
for the cellular source of HCC. In addition, LPC/biliary compartment not only has the 
capacity to differentiate into hepatocytes (7, 10, 16) but LPC also commonly found in 
dyplastic lesions and HCCs (22, 23, 40), suggesting that this compartment could be an 
alternative source for subsets of HCCs, in particular those with LPC signature. In support of 
this, both populations have been demonstrated to have the ability to induce HCC when 
transduced with a combination of H-Ras and SV40LT (24). Despite their know capacity to 
differentiate into HCC after forced expression of oncogenes, the relative contribution of these 
cell types to HCC formation in endogenous HCC models that occur in the setting of chronic 
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injury and inflammation remains unknown. Our fate tracing data support the hypothesis that 
hepatocytes constitute the main cellular source of HCC in mice and that LPC do not function 
as a source of HCC in mice. Our analysis not only includes several models in which HCCs 
expressed an abundance of progenitor markers, but also carcinogen-free models, in which 
HCC formation can be assessed without the possibly confounding preferential metabolization 
of carcinogenes by hepatocytes. Consistent with our data that 99.4% and 100% of HCC in the 
DEN+CCl4 and Mdr2ko model, respectively, were hepatocyte-derived, we never observed 
HCCs developing from genetically-labeled LPC. Due to the early age at which mice were 
injected, our hepatocyte labeling did not reach the levels that were seen in adult mice in 
previous studies (11, 32). As we did not label all hepatocytes but nonetheless only observed a 
single GFP-negative tumor out of a total of 186 tumors and none in the Mdr2ko model, we 
conclude that this tumor most likely arose from unlabeled hepatocytes. This is consistent with 
our finding that HCCs were never LPC-derived when we labeled the LPC/biliary 
compartment.  Moreover, we did not find any evidence supporting HSC, a recently suggested 
alternative source for liver progenitors and hepatocytes (17), as cellular source of HCC. Our 
findings are consistent with recent studies showing either a dominant or even exclusive role 
of hepatocytes in hepatocyte repopulation, even in settings where LPC expand and were 
considered a key source of newly generated hepatocytes (11-15). Likewise, our finding that 
murine HCCs are not derived from HSCs is consistent with our previous finding that HSCs do 
not contribute to the hepatocyte or progenitor pool in multiple chronic injury models in mice 
(38). In agreement with the data presented here, a recent study using Hnf1a-CreERT labeling 
of the biliary/LPC compartment, found no contribution of LPC to HCC in DEN- or Mdr2ko-
induced HCC (41), which complements findings presented here. However, in contrast to our 
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study, the authors did not positively identify the cellular source for HCC.  
Recent studies found that hepatocytes have a high degree of plasticity and de-differentiate 
into immature progenitors or biliary-type cells in response to specific signals (32, 33). These 
data are consistent with our finding that hepatocyte-derived tumor cells express progenitor 
markers, suggesting a similar ability of hepatocyte-derived tumor cells to de-differentiate into 
progenitor-like cells. It is likely that such a de-differentiation allows cells to adapt to specific 
challenges in the environment and presents an advantage for the tumor. Accordingly, tumors 
with progenitor signature have worse prognosis (23). Our study contains several limitations. 
Although we have confirmed hepatocyte-origin and excluded progenitor origin and HSC 
origin for a number of HCC models including various genotoxic and genetic models, we 
cannot fully exclude that progenitors have the ability to generate tumors in other settings. As 
a wide range of infectious, metabolic, genetic and toxic liver diseases can result in HCC 
development in patients, studies in additional hepatocarcinogenesis models – possibly 
employing humanized mice to mimick HCC arising in the setting of HBV- and HCV-induced 
hepatitis - are required to broaden the presented findings. Also, recent fate tracing studies in 
zebrafish have suggested that when hepatocyte proliferation is completely blocked – which so 
far has not been achieved in murine injury models – regeneration occurs to a significant 
degree from the biliary compartment (16). However, a “catastrophic” event with complete 
hepatocyte failure is characteristic for acute liver failure but not for HCC, where injury is 
typically mild and chronic, similar to the employed animal models.  Despite strong evidence 
in murine models, our study has only model character for human hepatocarcinogenesis. Our 
study mimicked several key features that are characteristic for human hepatocarcinogenesis, 
such as chronic liver injury, fibrosis and alterations of PTEN expression, but cannot address 
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possible intrinsic differences between mouse and human hepatocytes or progenitor cells. As 
such, the contribution of ductular reaction to functional hepatocytes in humans remains a 
matter of debate (40), and it therefore cannot be excluded that ductular reaction is a cellular 
source of HCC in patients. Future studies need to address the cellular origin of human HCC, 
e.g by showing that human hepatocytes have the same plasticity as mouse hepatocytes and are 
able to de-differentiate into progenitor cells and/or the use of humanized mice for fate tracing. 
 
MATERIALS AND METHODS 
All animal experiments were performed with approval from the Université catholique de 
Louvain Animal Welfare Committee and the Columbia University IACUC in accordance with 
EU regulations and NIH guidelines for the care and use of laboratory animals, respectively. 
Tracing of liver progenitor cells in hepatocarcinogenesis. To track the LPC and biliary 
cells, we used the previously reported OPN-iCreERT2;ROSA26RYFP mice (12). The 
transgenic mice have a CD1-enriched background and males were used in all experiments. To 
achieve Cre-LoxP recombination, tamoxifen (Sigma, T5648, Diegem, Belgium) dissolved in 
corn oil at a concentration of 30 mg/ml was injected intraperitoneally (i.p.) at 100 mg/kg body 
weight (BW) at day 21 pp unless specified otherwise. In all experiments, transgenic mice 
without tamoxifen injection (n ≥5) were used in parallel as negative control for Cre 
recombination. Mice had free access to water and food at all times. To determine the 
contribution of LPC to HCC, tamoxifen i.p. at d21 pp was followed by weekly DEN i.p. (35 
mg/kg BW) for 25 weeks starting at 6 weeks of age (n=44) (28). At the start of chronic DEN 
treatment and up to the end of the experiment, one group of mice was fed a standard rodent 
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chow (n=22) while another group (n=22) was placed on a high fat diet (HFD, 60% saturated 
fat, D12492 from Research Diets, USA). Because the effect of HFD was to hasten tumor 
development, and not the nature of the tumors, data are presented for the entire group.   In a 
second model a single i.p. of DEN (6 mg/kg BW, Sigma-Aldrich, N0258, Diegem, Belgium) 
at d15 pp and tamoxifen i.p. either at d 9-10  pp (n=16) or d 21-22 pp (n=25) and were 
sacrificed at 18 or 9 months, respectively. In a third experiment, tamoxifen-injected mice (d9-
10 pp) followed by a single i.p. of DEN (6 mg/kg BW- d15pp) and 20 weekly subsequent 
injections of CCl4 (0.5 µl/g body weight). Mice were sacrificed 2 to 4 weeks after last CCl4 
dose (n=6). The DEN+CCl4 model was additionally performed in K19-CreERT2 mice co-
expressing either ZsGreen or TdTomato Cre reporter, receiving tamoxifen at pnd10, and DEN 
at pnd 15, followed by 25 CCl4 injections. Other tamoxifen injected (pnd 21) OPN-Cre mice 
(n=12) were treated with choline-deficient, 0.15% ethionine-supplemented (CDE) diet for 50 
weeks starting at 8 weeks of age.  Mice were sacrificed at 58 weeks of age or earlier, when 
the general status of mice was altered (BW loss, decreased activity, or prostration). The 
DEN+CCl4 model was additionally performed in K19-CreERT2 mice (n=4) co-expressing 
either ZsGreen or TdTomato Cre reporter, receiving tamoxifen (80 µg/g i.p.) at d10 pp, and 
DEN at d15 pp, followed by 25 CCl4 injections. 
 
Tracing of hepatoytes in hepatocarcinogenesis. To genetically label hepatocytes, lox-stop-
lox mTom-mGFP Cre reporter mice (42) were infected with AAV8-TBG-Cre, resulting in 
mGFP expression in AAV8-TBG-Cre infected hepatocytes and their offspring. For this 
purpose, mice were injected with 1x1011 genome copies of AAV8-TBG-Cre (43) 
intravenously (i.v.) at d12 pp. To induce HCC, AAV8-TBG-Cre infected mice received a 
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single i.p. of DEN (25 mg/kg BW, Sigma-Aldrich) at d15 pp. Subsequently, hepatic 
carcinogenesis was promoted by chronic injury using three different models. Four weeks after 
receiving DEN, some mice were treated with a total of 15 injections of carbon tetrachloride 
(CCl4, 0.5 µl/g i.p., dissolved in oil at ratio of 1:3, given once weekly, n=7) as described (30). 
For hepatocyte tracing in mice receiving DEN+CCl4, only mice with at least 90% hepatocyte 
labeling in non-tumor sections were analyzed. Some mice were fed for 6 weeks with 0.1% 
3,5-diethoxycarbonyl-1,4-dihydro-collidin (DDC)-containing diet (n=4) starting 4 weeks after 
receiving DEN. Some mice were fed for 6 weeks with choline-deficient, 0.15% ethionine-
supplemented (CDE) diet starting 4 weeks after DEN injection (n=5).  
Mdr2 knockout-mediated hepatocarcinogenesis. To genetically label hepatocytes in the 
Mdr2ko model, lox-stop-lox ZsGreen Cre reporter mice (44) were infected with AAV8-TBG-
Cre, resulting in ZsGreen expression in AAV8-TBG-Cre infected hepatocytes and their 
offspring. Mdr2ko mice (FVB background) that had been bred with ZsGreen Cre reporter mice 
(C57Bl/6 background) and once backcrossed with Mdr2ko mice, were injected with 1x1011 
genome copies of AAV8-TBG-Cre (43) intravenously (i.v.) at d14 pp. Mdr2ko mice received 
additionally up to 25 CCl4 injections in order to accelerate hepatocarcinogenesis. Mice were 
sacrificed at the age of 12-14 months following HCC screening by ultrasound. 
PTEN-mediated hepatocarcinogenesis studies. As a non-genotoxic model of HCC, PTENf/f 
mice, some of which were additionally carrying the mTom/mGFP Cre reporter, were injected 
with AAV8-TBG-Cre (1x1011 genome copies i.v.) at 7 weeks of age, resulting in hepatocyte-
specific deletion of PTEN. To delete PTEN specifically in the progenitor/ductular 
compartment, Krt19-CreERT mice (31) were crossed with floxed PTEN mice, and injected 
with tamoxifen (100 µg/ i.p.) at 2 weeks of age.  
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LratCre-mediated HSC labeling. To determine whether HSCs might be a cellular source for 
HCC, LratCre mice co-expressing ZsGreen or TdTomato Cre reporters (44) were injected 
DEN (25 mg/kg BW, i.p) at d15 pp followed by 20 injections of CCl4. Mice were sacrificed 2 
weeks after the last CCl4 injection.  Mdr2ko mice co-expressing LratCre and ZsGreen or 
TdTomato served as second HCC model. Mice were sacrificed at the age of 12-14 months 
following HCC screening by ultrasound. 
Immunohistochemical and immunofluorescent analysis. Following sacrifice, and rapid 
excision of the liver rapidly, tumor and non-tumor tissue were macroscopicall identified and 
either fixed in 4% formalin for histological examination, or snap frozen in liquid nitrogen for 
gene expression analysis.  
For histological analysis, four µm formalin-fixed, paraffin-embedded liver sections and 
frozen liver sections were analyzed. For immunohistochemistry, slides were incubated for 1 
hour at 37ºC with primary antibodies against YFP (Ab6673, Abcam), cytokeratin 19 
(Developmental studies Hybridoma bank, University of Iowa), HNF4α (PP-H1415, R&D 
Systems or SC-6556, Santa Cruz Biotechnology), alpha feto protein (14550-1-AP, 
Proteintech), osteopontin (AF808, R&D Systems), alpha smooth muscle actin (Mybiosource 
 San Diego, CA), Ki67 (Tec3, Dako), desmin (RB-9014-P, Lab Vision), pancytokeratin 
(Z0622, Dako), CD31 (14-0311-81, Ebioscience), progenitor marker A6 (45) (a gift from Dr. 
Valentina Factor) or F4/80 (MCA497A64, AbD serotec), collagen IV (CL50451 AP-1, 
Cedarlane), Ki67 (Rabbit monoclonal, ThermoScientific), Gp73 (sc-48001, Santa Cruz) or 
glutamine synthetase (ab16802, Abcam). Detection was either performed using fluorescent 
secondary antibodies with various fluorescent conjugates anti-rabbit (donkey anti-rabbit, 
A21207, chicken-anti-rat A21472 or chicken anti-goat A21468, all used at 1:200, all 
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Invitrogen), or by HRP-conjugated secondary antibodies (anti-rat Ig-HRP, E0468, anti-goat 
Ig-HRP P0449, anti-mouse Envision K4001 or anti-rabbit Envision K4003, used at 1:50-
1:200, all DAKO), with subsequent diaminobenzidine (DAB) exposure and hematoxylin 
counterstaining. For DAB staining, serial sections were used. Fluorescent images were taken 
on a Nikon A1 confocal laser microscope (Nikon Instruments, Melville, NY, USA) using 20x 
standard lens or 40x and 60x oil-immersion lenses or an Axiovert 200 fluorescent microscope 
(Carl Zeiss, Munich, Germany). For some pictures and for quantification, four to six sections 
were merged. Non-fluorescent images were taken with a Zeiss microscope coupled to an 
AxioCam camera (MR3, Carl Zeiss, Munich, Germany). Omission of the first antibody with 
otherwise identical procedure or sample lacking specific protein expression served as negative 
control.  
Quantification of hepatocyte and tumor labeling ratio.  Labeling efficiency in the 
biliary/progenitor compartment was determined as previously reported 8 by quantification of 
K19+/YFP+ double positive cells relative to the total number of K19-positive cells in 25 
random non-tumor fields of view per section per mouse, and expressed as percentage.  
Timing for tamoxifen injection (d9 to d21) or DEN treatment at d15 did not modify labeling 
efficiency. The percentage of  A6+/YFP+ and AFP+/YFP+ double positive cells were 
quantified using the same methodology.  
For macroscopic imaging and determination of the percentage of GFP-labeled tumors, livers 
were visualized under a Leica MZ 16F fluorescent dissecting microscope. The ratio between 
green tumors and all tumors per mouse was determined and expressed as a percentage. To 
quantify the GFP labeling for hepatocytes, frozen sections from non-tumor tissue were used. 
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Labeling efficiency was evaluated by quantification of GFP+ hepatocytes relative to the total 
number of GFP+ and mTomato+ hepatocytes. and expressed as a percentage.  
The percentage of K19+/GFP+ double-positive cells was determined by quantification of 
K19+/GFP+ double-positive cells relative to total K19+ cell number in tumor and non-tumor 
areas in DEN+CCl4, DEN+CDE, DEN+DDC treated mice groups. The percentage of 
A6+/GFP+ double-positive cells was determined by the same approach. 
RNA isolation and qPCR.  RNA was isolated from cells and liver tissue by column 
purification and on-column DNAse treatment. After reverse transcription, mRNA levels were 
determined by quantitative real-time PCR on an Applied Biosystem 7300 PCR cycler, using 
Applied Biosystems Taqman primers and probes for Afp, Prom1, H19, mKi67, Golm1, 
Tspan8, Tff3 and Gpc3. All qPCRs were quantified using relative standard curves, and 
normalized to expression of 18s. mRNA levels in OPN-Cre samples were determined using 
SybrGreen and results expressed as fold induction relative to control untreated liver using the ΔΔCt!method. 
Determination of hepatocyte and non-parenchymal cell markers in AAV8-TBG-Cre-
labeled liver cells. To determine which hepatic cell types were labeled by AAV8-TBG-Cre, 
ZsGreen Cre reporter mice were infected with AAV8-TBG-Cre. One week later, mice were 
sacrificed. Following perfusion with collagenase, green-fluorescence cells were sorted from 
the entire liver cell suspensions by FACS. After RNA isolation and reverse transcription, 
qPCR was employed to measure hepatocyte markers (Alb, Ttr), cholangiocyte markers (Krt7, 
Krt19), HSC markers (Des, Lrat), endothelial cell makers (Pecam, vWf), and macrophage 
markers (Emr1, Cd68). To determine the percent of these markers in the isolated green-
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fluorescent cell fraction, cDNA from pure reference populations of primary cholangiocytes, 
HSCs, endothelial cells and hepatic macrophages (38) were used. 
Comparative genomic hybridization and syntenic analysis. Custom-designed 8x60k arrays 
(AMADID 41078 were used for array CGH (Agilent, Bloebingen, Germany). 19 different 
formalin-fixed and paraffin embedded HCC nodules and two unaffected liver tissues were 
microdissected and genomic DNA was extracted using DNAeasy FFPE kit (QIAGEN; 
Hildesheim, Germany), as described (46). 125 ng gDNA from test and control DNA were 
labeled with Cy3-dUTP and Cy5-dUTP, respectively, using CGH labeling protocol of Enzo 
Life Sciences (Enzo, Loerrach, Germany). Purification of labeled nucleotides, hybridization, 
scanning and data extraction were performed according to manufacturer’s instructions and as 
described (47). 50% of estimated proportion of tumor cells - based on H&E microscopic 
assessments - were used for the CGHcall function (46, 47). Human syntenic regions were 
queried using an in-house compiled R-Function (REF21) and Biomart database 
(www.biomart.com). Ward’s method and Euclidean distance were employed to hierarchically 
cluster and visualize the copy number profiles, using again the in-house written R function. 
The aCGH set described in (34)  was downloaded from GEO 
(http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE8351) and analyzed as described 
(47) .  
Statistical evaluation. Statistical analysis was performed using Prism (GraphPad, San Diego, 
CA). Differences between two groups were calculated using Student’s t-test (paired t-test) or 
Mann-Whitney U-test. Significance of differences between multiple groups was determined 
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by one-way ANOVA, followed by Dunnett’s or Dunns post-hoc test. All data are expressed 
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Figure 2. Genotoxic HCC derives from hepatocytes. mTom-mGFP Cre reporter mice (n=10) were 
infected with AAV8-TBG-Cre to selectively label hepatocytes, followed by treatment with DEN and 15 CCl4 
injections for HCC induction. A-C. Representative photographs and fluorescent images of livers from DEN
+CCl4 treated mice (A) and H&E- and GFP-stained liver sections at low (B) and high (C) magnification, 
including a mTom-mGFP-negative control. D. Quantification of GFP-labeled hepatocytes and tumors 
(average of all mice). E. Typical HCC features were confirmed by collagen IV staining, increased Ki67 and 
glutamine synthetase and altered Gp73 and β-catenin staining.  F-G. Karyoplot (F) of comparative genomic 
hybridization array from 19 tumors (from different 8 different mice). Long (q) arm is shown, dark band 
representing G-C rich domain. Synteny analysis (G) reveals that loci with chromosomal losses (blue) or 
amplifications (red) in the DEN+CCL4 model are also found in human HCCs. H-I. HCC markers (H) and 
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Figure 3. HCCs derive from hepatocytes in the Mdr2ko HCC model. ZsGreen Cre reporter mice (n=8) 
were infected with AAV8-TBG-Cre to selectively label hepatocytes, and sacrificed at the age of 12-14 
months. A-C. Representative photographs and fluorescent images of whole livers from Mdr2ko mice (A) as 
well as low power H&E- and DAP-stained frozen liver sections at low (B) and high (C) power including a 
ZsGreen-negative control. D. Quantification of GFP-labeled hepatocytes and tumors (average of all mice). 
E. Co-staining demonstrated that HNF4α-positive tumor cells were ZsGreen positive.  F. Typical HCC 
features were confirmed by increased Ki67 expression and altered collagen IV staining.  G-H. HCC markers 
(F) and progenitor markers (G) were determined by qPCR.  Scale bar A:1 cm; B: 300 µm; C,E 50 µm; F: 
500 µm. ** p<0.01. 
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Figure 4. HCCs are not derived from hepatic stellate cells. A-D. LratCre transgenic mice expressing 
ZsGreen Cre reporter (n=4) were treated with DEN and 15 CCl4 injections for HCC induction. Representative 
photographs and fluorescent images of livers from DEN+CCl4 treated mice (A) as well as low and high 
power H&E- and Hoechst-stained frozen liver sections at low and high magnification show green fluorescent 
HSCs but no green fluorescent tumor cells derived from HSCs (B). Typical HCC features were confirmed by 
collagen IV staining and increased Ki67 expression (C). ZsGreen-positive cells colocalized with HSC marker 
desmin (D). E-H. Mdr2ko mice expressing LratCre and the Zs1Green Cre reporter (n=8) were sacrificed at 
the age of 12 months. Representative photographs and fluorescent images of whole livers (E) as well as low 
and high power H&E- and Hoechst-stained frozen liver sections at low and high magnification show green 
fluorescent HSCs but no green fluorescent tumor cells derived from HSCs  (F). Typical HCC features were 
confirmed by increased Ki67 expression and altered collagen IV staining (G). ZsGreen-positive cells 
colocalized with HSC marker desmin (H). Scale bar: A and E: 5 mm; B (left panel) and F (left panel): 500 µm; 
















































Table 1: LPC tracking in HCC models.  
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